Navigation Links
India's Asthma Drug Market Will Exceed $400 Million in 2014
Date:12/7/2010

BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that India's asthma drug market will grow from $246 million in 2009 to $403 million in 2014, representing an annual growth rate of ten percent. According to the Emerging Markets report entitled Asthma in India, this growth will be fueled by improved access to medical care, a growing drug-treated population and a rising number of higher-income, brand-conscious asthma patients demanding more-efficacious agents.  

"At $246 million, India's asthma market is close to some European Union countries in dollar terms," said Decision Resources Analyst Manashi Sherawat, M.Sc., Ph.D. "In 2009, multinational pharmaceutical companies accounted for five percent of total sales in the Indian asthma market and while uptake of Western-branded asthma drugs will increase by 2014, these drugs will face fierce competition from less-expensive Indian brands and generics."

According to the report, fixed-dosed combination drugs represent a major opportunity for multinational pharmaceutical companies. The use of combination therapy as maintenance treatment will increase as medical practice in India shifts from treating asthma on an as-needed basis toward treating it as a chronic disease that requires maintenance treatment. Specifically, Indian specialists anticipate that fixed-dosed combination therapies such as long-acting beta(2) agonist (LABA)/inhaled corticosteroid (ICS) will experience the highest uptake.

"Indian specialists struggle with patient compliance when treating asthma. The importance of consistent maintenance therapy is paramount because improved disease outcomes are not achieved unless maintenance therapies are administered consistently. The Indian asthma market would benefit from new, more-convenient therapies, which would boost patient compliance," added Dr. Sherawat.

The new report features extensive primary research of Indian specialists as well as epidemiology data.

About Emerging Markets ReportsDecision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesLisa Osgood781-993-2606losgood@dresources.comDecision Resources, Inc.Christopher Comfort781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs
2. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
3. Boston Scientific Completes Acquisition of Asthmatx
4. Due to Rising Costs of Asthma and Chronic Obstructive Pulmonary Disease Drugs, Managed Care Organization Pharmacy Directors Will be Forced to Tighten Their Formularies
5. Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010
6. Boston Scientific to Acquire Asthmatx
7. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
8. FDAs New Safety Controls for LABA-Containing Drugs Will Impact Prescribing of Single-Agent ICS and LABA/ICS Combination Therapies for the Treatment of Asthma
9. Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA
10. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
11. Teva Respiratory to Host Phillies Asthma Awareness Night Featuring Free Asthma and Exercise-Induced Bronchospasm Screenings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
(Date:3/27/2017)... March 27, 2017  A new survey ... that Medicare,s Competitive Bidding Program (CBP) significantly reduced beneficiary ... The lack of choice forces beneficiaries to switch to ... health consequences. AADE,s survey is the ... and others pointing out the inherent problems with the ...
(Date:3/27/2017)... 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" ... MD is pleased to announce it has received conditional ... the TSX Venture Exchange.  Receiving the ... of significant achievements for Invictus-MD. Some of which include: ... AB Laboratories Inc. ("AB Labs"), a Licensed Producer under ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... million people suffering from acne, access to quality care can be limited while the ... skincare company that offers customized prescription acne care for every customer online, today released ...
(Date:3/28/2017)... ... 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics ... in the country to sit on the 2017 National Advisory Board for Allergan’s Facial ... Dr. Harper helped propel the clinic from a small start-up to number 78 in ...
(Date:3/28/2017)... ... 2017 , ... Public relations pros work hard to earn placements and ... While many results are clear, much of PR is hard to quantify. Goal-setting and ... to measurement, firms should always take an all-inclusive approach that takes both traditional and ...
(Date:3/28/2017)... ... ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders and ... to the discussion of dealing with excess skin oil. “Oily skin is a challenge to ... can help remove the oily shine while keeping the skin fresh and clean,” says Dr. ...
Breaking Medicine News(10 mins):